Fière D, Martin C, Vu Van H, Coiffier B, Felman P, Bryon P A, Favre-Gilly J, Revol L
Sem Hop. 1979;55(13-14):633-8.
Between november 1974 and august 1976, 100 acute myeloïd leukemias were treated by the same protocol L. 275. Induction treatment was daunorubicine, vincristine, cytosine arabinoside, in one intensive course for patients under 65 and cyclophosphamide (CPM), VCR and CAR in a less intensive and repetitive courses for patients over 65. In remission, there were three phases: consolidation, prevention of central nervous system leukemia, maintenance. All patients in remission received an androgenotherapy and two groups were randomised: chemotherapy and chemotherapy plus BCG. 68 patients were in complet remission (CR) 61 out of 80 patients under 65 and 7 out of 20 over 65. Median duration of first remission was 12 months. Median duration of survival was 13 months for all patients, 15 months for patients under 65, 3 months for patients over 65, and 22 months for 68 patients in CR. Survival of patients receiving BCG was slightly better than patients without BCG.
1974年11月至1976年8月期间，100例急性髓细胞白血病患者采用相同的L. 275方案进行治疗。诱导治疗方面，65岁以下患者采用柔红霉素、长春新碱、阿糖胞苷进行一个强化疗程，65岁以上患者采用环磷酰胺（CPM）、长春新碱（VCR）和阿糖胞苷（CAR）进行强度较低的重复疗程。缓解期分为三个阶段：巩固、预防中枢神经系统白血病、维持。所有缓解期患者均接受雄激素治疗，并随机分为两组：化疗组和化疗加卡介苗组。68例患者完全缓解（CR），其中65岁以下80例患者中有61例，65岁以上20例患者中有7例。首次缓解的中位持续时间为12个月。所有患者的中位生存时间为13个月，65岁以下患者为15个月，65岁以上患者为3个月，68例CR患者为22个月。接受卡介苗治疗的患者生存率略高于未接受卡介苗治疗的患者。
